Translate
Galectin Therapeutics Inc
About
Galectin Therapeutics Inc (NASDAQ:GALT) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 31 2026
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Mar 17 2026
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Feb 26 2026
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
Dec 19 2025
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Nov 14 2025
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Recent Videos
My Insight on Galectin Therapeutics' Board Director Change
Mar 22, 2026
How to Buy Galectin Therapeutics Inc Stock (GALT)
Mar 19, 2026
Galectin Therapeutics Belapectin Development Program for Treatment of Metabolic Dysfunction Associat
Mar 11, 2026
Galectin Therapeutics 8-K: My Take on the Director's Exit
Jan 15, 2026
Financials
Revenue
$0
Market Cap
$175.76 M
EPS
-0.48